Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity

Enhancing Pharmacokinetics, Tumor Accumulation, and Antitumor Efficacy by Elastin-Like Polypeptide Fusion of Interferon Alpha

(2015) Jin Hu et al.   ADVANCED MATERIALS

The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2015/16: Transporters

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Experimental design and analysis and their reporting: new guidance for publication in BJP

(2015) Michael J Curtis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP

(2015) John C McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

(2015) Christopher Southan et al.   NUCLEIC ACIDS RESEARCH

A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog

(2014) Lintao Song et al.   BIOMATERIALS

Hydrodynamic delivery of FGF21 gene alleviates obesity and fatty liver in mice fed a high-fat diet

(2014) Mingming Gao et al.   JOURNAL OF CONTROLLED RELEASE

FGF21-based pharmacotherapy – potential utility for metabolic disorders

(2014) Ruth E. Gimeno et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Inventing new medicines: The FGF21 story

(2014) Alexei Kharitonenkov et al.   Molecular Metabolism

A Novel Approach to Improve the Function of FGF21

(2013) Richard Smith et al.   BIODRUGS

Discussion about Several Potential Drawbacks of PEGylated Therapeutic Proteins

(2013) Fan Zhang et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome

(2013) Jun Zhang et al.   DRUG DISCOVERY TODAY

PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins

(2013) M. Schlapschy et al.   PROTEIN ENGINEERING DESIGN & SELECTION

PEGylation: An Approach for Drug Delivery. A Review

(2012) Aviral Jain et al.   CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS

A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life

(2012) Jeffrey L. Cleland et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

(2012) Randy Hecht et al.   PLoS One

Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice

(2011) Xiaoyan Sheng et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Strategies for extended serum half-life of protein therapeutics

(2011) Roland E Kontermann   CURRENT OPINION IN BIOTECHNOLOGY

Impact of albumin on drug delivery — New applications on the horizon

(2011) Bakheet Elsadek et al.   JOURNAL OF CONTROLLED RELEASE

State of the art in PEGylation: The great versatility achieved after forty years of research

(2011) Gianfranco Pasut et al.   JOURNAL OF CONTROLLED RELEASE

A Better Anti-Diabetic Recombinant Human Fibroblast Growth Factor 21 (rhFGF21) Modified with Polyethylene Glycol

(2011) Zhifeng Huang et al.   PLoS One

Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives

(2010) Katrin Knop et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Elastin-like polypeptides: Biomedical applications of tunable biopolymers

(2010) Sarah R. MacEwan et al.   BIOPOLYMERS

PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel

(2010) Yong Zhang et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines

(2010) Carol Kilkenny et al.   JOURNAL OF GENE MEDICINE

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

(2009) Volker Schellenberger et al.   NATURE BIOTECHNOLOGY

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

(2008) J. Xu et al.   DIABETES

Serum Levels of the Adipokine FGF21 Depend on Renal Function

(2008) S. Stein et al.   DIABETES CARE